Suspected or Documented Gram-negative Bacterial InfectionPhase 2/3NCT03969901
Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
A Phase 2/3 study testing IMI/REL and Oral Switch in people with Suspected or Documented Gram-negative Bacterial Infection, run by Merck Sharp & Dohme LLC at 67 sites in 18 countries.
Trial summary
The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial infection. Read more about this study
- Who is it for?
- Ages Up to 17 years
- Conditions the study is for
- Suspected or Documented Gram-negative Bacterial Infection
- What is being tested?
- IMI/REL and Oral Switch
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 115 participants
- Where
- 67 sitesin 18 countries
- Study dates
- 8 Oct 2019to 7 May 2024
- Phase
- Phase 2/3
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Requires hospitalization and treatment with intravenous (IV) antibacterial therapy for confirmed or suspected gram-negative bacterial infection (in the absence of meningitis), and is expected to require hospitalization through completion of IV study intervention, with at least 1 of the following primary infection types: Hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP); complicated intra-abdominal infection (cIAI); or complicated urinary tract infection (cUTI).
- For Age Cohorts 4 and 5, participant is at least 37 weeks postmenstrual age at the time of signing the informed consent/assent.
- If female, must not be pregnant or breastfeeding, and at least 1 of the following conditions must apply: must not be a woman of childbearing potential (WOCBP); OR, if a WOCBP, must agree to follow contraceptive guidance during the intervention period and for at least 24 hours after the last dose of study intervention.
- Has sufficient intravascular access to receive study drug through an existing peripheral or central line.
Who cannot join
- Is expected to survive less than 72 hours.
- Has a concurrent infection that would interfere with evaluation of response to the study antibacterials (imipenem/cilastatin/relebactam (IMI/REL) or Active Control), including any of the following: endocarditis; osteomyelitis; meningitis; prosthetic joint infection; active pulmonary tuberculosis; disseminated fungal infection; concomitant infection at the time of randomization that requires non-study systemic antibacterial therapy in addition to IV study treatment or oral step-down therapy (medications with only gram-positive activity [e.g., vancomycin, linezolid] are allowed).
- Has HABP/VABP caused by an obstructive process, including lung cancer (or other malignancy metastatic to the lungs resulting in pulmonary obstruction) or other known obstruction.
- Has a cUTI, with any of the following: complete obstruction of any portion of the urinary tract (i.e., requiring a permanent indwelling urinary catheter or instrumentation); documented reflux of ileal loop urinary diversion; suspected or confirmed perinephric or intrarenal abscess; suspected or confirmed prostatitis, urethritis, or epididymitis; trauma to pelvis/urinary tract; presence of indwelling urinary catheter which cannot be removed at study entry.
- Has any of the following medical conditions at screening: history of a seizure disorder (requiring ongoing treatment with anti-convulsive therapy or prior treatment with anti-convulsive therapy within the last 3 years); cystic fibrosis; history of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to IMI, or to any carbapenem, cephalosporin, penicillin, or other β-lactam agent, or to other β-lactamase inhibitors (e.g., tazobactam, sulbactam, clavulanic acid, avibactam).
- Has a history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might expose the participant to risk by participating in the study, confound study results, or interfere with the participant's participation for the full duration of the study.
Show all 18Show fewer
- If less than 3 months of age, has received more than 72 hours of empiric antibacterial treatment for suspected meningitis prior to initiation of IV study intervention.
- For all Age Cohorts, provided all other eligibility criteria are met, the following participants may be enrolled:
- A participant failing prior antibiotic therapy for a current episode of cUTI or HABP/VABP who: Has received the prior antibacterial treatment for at least 48 hours; Has persistent clinical or radiographic findings clearly indicating ongoing infection; Fulfills other laboratory or microbiology criteria for enrollment
- A participant failing prior antibiotic therapy for a current episode of cIAI who: Has received the prior antibacterial treatment for at least 48 hours; Has persistent clinical or radiographic findings clearly indicating ongoing infection; Fulfills other laboratory or microbiology criteria for enrollment; Has planned operative intervention no more than 24 hours after first dose of study treatment; Has not received any further nonstudy antibiotics postoperatively
- If 3 months of age or older, or <3 months of age without suspected meningitis, has received potentially therapeutic antibacterial therapy (e.g., with gram-negative activity), including bladder infusions with topical urinary antiseptics or antibacterial agents, for a duration of more than 24 hours during the 48 hours preceding the first dose of study intervention.
- Is anticipated to be treated with any of the following medications: valproic acid or divalproex sodium (or has used valproic acid or divalproex sodium in the 2 weeks prior to screening) through 24 hours after completion of the final dose of IV study intervention for participants who receive IMI/REL or carbapenem; concomitant IV, oral, or inhaled antimicrobial agents with gram-negative activity, in addition to those designated in the study intervention groups, during the course of all (IV/oral) study intervention; planned receipt of suppressive/prophylactic antibiotics with gram-negative activity after completion of study intervention.
- Is currently participating in or has participated in an interventional clinical study with an investigational compound or device within 30 days prior to screening.
- Has enrolled previously in the current study and been discontinued or has received REL for any other reason.
- Has an estimated creatinine clearance (based on the Cockcroft-Gault equation, for participants ≥12 years of age or estimated glomerular filtration rate (eGFR), based on the modified Schwartz equation, for participants <12 years of age below that specified for the appropriate age range; or requires peritoneal dialysis, hemodialysis, or hemofiltration.
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × upper limit of normal (ULN) at the time of screening. NOTE: Patients with acute hepatic failure or acute decompensation of chronic hepatic failure should also be excluded.
- Is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence.
- Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or Sponsor staff directly involved with this study.
Trial locations and contacts
67 sites in 18 countries.
67 sites in 18 countries
United States8 sites
University of New Mexico ( Site 0358)
Albuquerque, New Mexico, 87106
Tufts Medical Center-Floating Hospital for Children ( Site 0350)
Boston, Massachusetts, 02111
Miller Children's & Women's Hospital ( Site 0349)
Long Beach, California, 90806
West Virginia University Ruby Memorial Hospital ( Site 0344)
Morgantown, West Virginia, 26506
Children's Hospital of Richmond at VCU ( Site 0359)
Richmond, Virginia, 23298
University Hospital ( Site 0360)
San Antonio, Texas, 78229
Rady Children's Hospital-San Diego ( Site 0347)
San Diego, California, 92123
Banner University Medical Center ( Site 0356)
Tucson, Arizona, 85724
Russia8 sites
Pediatric Hematology Oncology and Immunology Centre n.a. D.Rogachev. ( Site 0233)
Moscow, Moscow, 117197
Morozovskaya Children City Clinical Hospital ( Site 0241)
Moscow, Moscow, 119049
State Budgetary Healthcare Institution of Novosibirsk Region City Childrens Clinical Emergency Hospi
Novosibirsk, Novosibirsk Oblast, 630011
Children s City Clinical Hospital 5 n.a. N.F. Filatov ( Site 0235)
Saint Petersburg, Sankt-Peterburg, 192289
St.Petersburg State Pediatric Medical University ( Site 0236)
Saint Petersburg, Sankt-Peterburg, 194100
Children's City Clinical Hospital #1 ( Site 0237)
Saint Petersburg, Sankt-Peterburg, 198205
Smolensk Regional Clinical Hospital ( Site 0231)
Smolensk, Smolensk Oblast, 214018
Regional Childrens Clinical Hospital ( Site 0400)
Vologda, Vologda Oblast, 160022
Bulgaria6 sites
UMHAT Deva Maria. EOOD ( Site 0165)
Burgas, 8127
MHAT City Clinic Sv. Georgi EOOD ( Site 0167)
Montana, 3400
UMHAT Dr. Georgi Stranski EAD ( Site 0174)
Pleven, 5800
UMHAT Kanev AD ( Site 0168)
Rousse, 7002
UMHAT Kanev AD ( Site 0169)
Rousse, 7002
MHAT Dr. Ival Seliminski ( Site 0173)
Sliven, 8800
Colombia5 sites
Clinica de la Costa S.A.S. ( Site 0264)
Barranquilla, Atlántico, 080020
Sociedad de Cirugía de Bogotá - Hospital de San Jose ( Site 0265)
Bogotá, Bogota D.C., 11001000
Fundacion Hospital Infantil Universitario de San Jose ( Site 0268)
Bogotá, Bogota D.C., 111211
Fundacion Valle del Lili ( Site 0266)
Cali, Valle del Cauca Department, 760032
Fundacion Hospital San Vicente de Paul ( Site 0269)
Medellín, Antioquia, 050010
Turkey (Türkiye)5 sites
Cukurova University Medical Faculty ( Site 0200)
Adana, 01330
Ankara Universitesi Tip Fakultesi. ( Site 0202)
Ankara, 06590
Eskisehir Osmangazi University Medical ( Site 0201)
Eskişehir, 26480
SBU Sariyer Hamidiye Etfal Egitim ve Arastirma Hastanesi ( Site 0198)
Istanbul, 34453
Ege Universitesi Tıp Fakultesi Hastanesi ( Site 0199)
Izmir, 35100
Ukraine5 sites
SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 0121)
Dnipro, Dnipropetrovsk Oblast, 49100
Ivano-Frankivsk Regional Children Clinical Hospital ( Site 0131)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76014
Kharkiv City Children Hospital 16 ( Site 0130)
Kharkiv, Kharkiv Oblast, 61075
Communal non-commercial enterprise "Kryvorizka city clinical hospital 16" of Kryvyy Rig city council
Kryvyy Rig, Dnipropetrovsk Oblast, 50082
Municipal Enterprise Children's City Clinical Hospital in Poltava City Council ( Site 0122)
Poltava, Poltava Oblast, 36004
Israel4 sites
Rambam Medical Center ( Site 0189)
Haifa, 3109601
Hadassah Ein Karem Hebrew University Medical Center ( Site 0188)
Jerusalem, 9112001
Schneider Children's Medical Center ( Site 0187)
Petah Tikva, 4920235
Chaim Sheba Medical Center ( Site 0190)
Ramat Gan, 5262100
Mexico4 sites
Centenario Hospital Miguel Hidalgo-Pediatrics Department ( Site 0290)
Aguascalientes, 20259
Hospital del Nino y Adolescente Morelense ( Site 0286)
Emiliano Zapata, Morelos, 62765
Instituto Nacional de Pediatria ( Site 0291)
Mexico City, 04530
Hospital General de Tijuana ( Site 0284)
Tijuana, Estado de Baja California, 22000
France3 sites
Hopital Francois Mitterand ( Site 0146)
Dijon, Cote-d Or, 21000
Hopital Jeanne de Flandre ( Site 0145)
Lille, Hauts-de-France, 59120
Hopitaux Pediatriques CHU Lenval ( Site 0143)
Nice, Alpes-Maritimes, 06200
Greece3 sites
University of Athens - Aghia Sophia Childrens Hospital ( Site 0243)
Athens, Attica, 115 27
Pan and Aglaia Kyriakou Children s Hospital ( Site 0247)
Athens, Attica, 11527
Hippokration General Hospital of Thessaloniki ( Site 0244)
Thessaloniki, 546 42
Poland3 sites
Instytut Centrum Zdrowia Matki Polki ( Site 0223)
Lodz, Łódź Voivodeship, 93-338
SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 0226)
Łomianki, Masovian Voivodeship, 05-092
Wojewodzki Szpital Zespolony im. Rydgiera ( Site 0220)
Torun, Kuyavian-Pomeranian Voivodeship, 87-100
South Africa3 sites
Empilweni Services and Research Unit ( Site 1557)
Johannesburg, Gauteng, 2001
Chris Hani Baragwanath Academic Hospital ( Site 0156)
Johannesburg, Gauteng, 2013
Molotlegi Street ( Site 0155)
Pretoria, Gauteng, 0208
Spain3 sites
Hospital Infantil Universitario Nino Jesus ( Site 0114)
Madrid, 28009
Hospital Universitario La Paz ( Site 0113)
Madrid, 28046
Hospital Universitario Virgen del Rocio ( Site 0115)
Seville, 41043
Hungary2 sites
Debreceni Egyetem Klinikai Kozpont ( Site 0100)
Debrecen, Hajdú-Bihar, 4032
Szabolcs-Szatmar-Bereg Megyei Kórházak és Egyetemi Otatókórház-Gyermekosztály ( Site 0105)
Nyíregyháza, Szabolcs-Szatmár-Bereg, 4400
Philippines2 sites
University of the Philippines-Philippine General Hospital ( Site 0318)
Manila, National Capital Region, 1000
Philippine Children s Medical Center ( Site 0317)
Quezon City, National Capital Region, 1104
Chile1 site
Hospital Roberto del Río ( Site 0802)
Santiago, Region M. de Santiago, 8380418
Norway1 site
Haukeland Universitetssjukehus ( Site 0500)
Bergen, Hordaland, 5009
About this study
Official title: A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection
The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial infection. Participants are expected to require hospitalization through completion of intravenous (IV) study intervention, and have at least one of the following primary infection types: hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP); complicated intra-abdominal infection (cIAI); or complicated urinary tract infection (cUTI). Participants will be randomized in a 3:1 ratio to receive IMI/REL or active control. This study will also evaluate the efficacy of IMI/REL by assessing all-cause mortality at Day 28 post-randomization, as well as clinical and microbiological response to treatment. It will also evaluate the pharmacokinetics of IMI/REL.
- Being tested
- IMI/REL, Active Control, Oral Switch
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IMI/RELDrug
Also called MK-7655A
Age-based dosing:
- 12 to <18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours
- 6 to <12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours
- 2 to <6 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours
- 3 months to <2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours
- Birth to <3 months, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
Active ControlDrug
All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents.
Oral SwitchDrug
All oral switch medications will be investigator's choice from a list of acceptable approved agents for infection types cIAI, and cUTI and will be given per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines. Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
| Study group | Role | What they receive |
|---|---|---|
| IMI/REL | Experimental | Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion for a minimum of 5 days (with optional investigator's choice of locally sourced oral switch medication after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion for a minimum of 7 days up to a maximum of 14 days. Participants with bacteremia or Pseudomonas aeruginosa infection will receive IMI/REL via IV infusion for 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines. Receives: Drug: IMI/REL; Drug: Oral Switch |
| Active Control | Active comparator | Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional investigator's choice of locally sourced oral switch medication after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. Participants with bacteremia or Pseudomonas aeruginosa infection will receive active control via IV infusion for 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents. Receives: Drug: Active Control; Drug: Oral Switch |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With One or More Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants with AEs are presented.
Measured: Up to 28 days
Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study medication due to an AE are presented.
Measured: Up to 14 days
Secondary outcomes (12)
Percentage of Participants With All-cause Mortality Through Day 28
For each participant, survival status was assessed at Day 28 post-randomization. The percentage of participants with all-cause mortality through Day 28 is presented.
Measured: Up to Day 28
Percentage of Participants With a Favorable Clinical Response at End of Therapy (EOT)
A favorable clinical response at EOT requires an assessment of "cure" or "improved". Cure is defined as all preintervention signs and symptoms of the index infection have resolved (or returned to "preinfection status", with no new symptoms) AND no additional antibacterial intervention is required for the index infection. Improved is defined as the majority of preintervention signs and symptoms of the index infection have improved or resolved (or returned to "preinfection status", with no new symptoms) AND no additional antibacterial intervention is required. The percentage of participants with a favorable clinical response at EOT is presented.
Measured: Day 5 up to Day 14
Percentage of Participants With a Favorable Clinical Response at Early Follow-Up (EFU)
A favorable clinical response at EFU requires an assessment of "cure" or "sustained cure". Cure is defined as all preintervention signs and symptoms of the index infection have resolved (or returned to "preinfection status", with no new symptoms) AND no additional antibacterial intervention is required for the index infection. Sustained cure is defined as a clinical response for the prior visit (EOT or EFU) being defined as "cure". The percentage of participants with a favorable clinical response at EFU is presented.
Measured: Day 12 up to Day 28
Percentage of Participants With a Favorable Clinical Response at Late Follow-Up (LFU)
A favorable clinical response at LFU requires an assessment of "cure" or "sustained cure". Cure is defined as all preintervention signs and symptoms of the index infection have resolved (or returned to "preinfection status", with no new symptoms) AND no additional antibacterial intervention is required for the index infection. Sustained cure is defined as a clinical response for the prior visit (EOT or EFU) being defined as "cure". The percentage of participants with a favorable clinical response at LFU is presented.
Measured: Baseline and Day 19 up to Day 42
Percentage of Participants With a Favorable Microbiological Response at End of Therapy (EOT)
A favorable microbial response is defined as eradication or presumed eradication. Eradication is defined as one of the following: A lower respiratory tract culture taken at the EOT visit shows eradication of the pathogen found at study entry for HABP/VABP; An intra-abdominal culture taken at the EOT visit shows eradication of the pathogen found at study entry for cIAI; A urine culture taken at the EOT visit shows eradication of the uropathogen (reduced to <103 CFU/mL) found at study entry for cUTI. Presumed eradication is defined as no specimen taken because participant is deemed clinically improved or cured of the pathogen found at study entry. The percentage of participants with a favorable microbial response at EOT is presented.
Measured: Day 5 up to Day 14
Percentage of Participants With a Favorable Microbiological Response at End of Follow-Up (EFU)
A favorable microbiological response at EFU is defined as eradication or presumed eradication. Eradication is defined as one of the following: A lower respiratory tract culture taken at the EFU visit shows eradication of the pathogen found at study entry for HABP/VABP; An intra-abdominal culture taken at the EFU visit shows eradication of the pathogen found at study entry for cIAI; A urine culture taken at the EFU visit shows eradication of the uropathogen (reduced to <103 CFU/mL) found at study entry for cUTI. Presumed eradication is defined as no specimen taken because participant is deemed clinically improved or cured of the pathogen found at study entry. The percentage of participants with a favorable microbial response at EFU is presented.
Measured: Day 12 up to Day 28
Percentage of Participants With a Favorable Microbiological Response at Late Follow-Up (LFU)
A favorable microbiological response at LFU is defined as eradication or presumed eradication. Eradication is defined as one of the following: A lower respiratory tract culture taken at the LFU visit shows eradication of the pathogen found at study entry for HABP/VABP; An intra-abdominal culture taken at the LFU visit shows eradication of the pathogen found at study entry for cIAI; A urine culture taken at the LFU visit shows eradication of the uropathogen (reduced to <103 CFU/mL) found at study entry for cUTI. Presumed eradication is defined as no specimen taken because participant is deemed clinically improved or cured of the pathogen found at study entry. The percentage of participants with a favorable microbial response at LFU is presented.
Measured: Day 19 up to Day 42
Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of Imipenem Following Administration of IMI/REL
AUC0-24 is a measure of the total amount of drug in the plasma from the dose to Hour 24. Blood samples were collected to determine the AUC0-24 of imipenem.
Measured: On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.
Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of Relebactam Following Administration of IMI/REL
AUC0-24 is a measure of the total amount of drug in the plasma from the dose to Hour 24. Blood samples were collected to determine the AUC0-24 of relebactam.
Measured: On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.
Concentration at End of Infusion (Ceoi) of Imipenem Following Administration of IMI/REL
Ceoi is the concentration of the drug at the end of infusion. Blood samples for analysis were collected within 10 minutes of the end of infusion to determine the Ceoi of imipenem.
Measured: At the end of the first infusion on Day 1.
Concentration at End of Infusion (Ceoi) of Relebactam Following Administration of IMI/REL
Ceoi is the concentration of the drug at the end of infusion. Blood samples for analysis were collected within 10 minutes of the end of infusion to determine the Ceoi of relebactam.
Measured: At the end of the first infusion on Day 1.
Percentage of Time Imipenem Concentration Is Above Minimum Inhibitory Concentration (%T>MIC of Imipenem) Following Administration of IMI/REL
Percentage of Time Imipenem Concentration Is Above Minimum Inhibitory Concentration (%T>MIC) is defined as the cumulative percentage the drug concentration exceeds the MIC at steady state pharmacokinetic conditions. Blood samples were collected to determine %T>MIC of imipenem. %T>MIC is calculated using baseline microbiological response values.
Measured: On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2019
- Study start8 Oct 2019
- Primary completion7 May 2024
- Study completion7 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Suspected or Documented Gram-negative Bacterial InfectionStudies of the same condition, open and under way.
- More trials run by Merck Sharp & Dohme LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 115 participants (actual)
Sponsor and investigators
- Lead sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Medical Director, Study director, Merck Sharp & Dohme LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03969901
- Sponsor's protocol ID
- 7655A-021
- Other IDs
- MK-7655A-021, 2019-000338-20, 2019
- Status last verified
- Dec 2025
- First submitted
- 28 May 2019
- Last updated
- 5 Feb 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Publications
Bradley JS, Norice CT, Roilides E, Shevelev A, Jurkiewicz B, Piedrahita JA, Macias-Parra M, Monroy Colin VA, Dalgic N, Koseoglu S, Masih I, Nair P, Young K, Hilbert DW, Nieddu GT, Patel M, Huntington JA, Paschke A, Bruno CJ. Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections. Pediatr Infect Dis J. 2026 Jul 7. doi: 10.1097/INF.0000000000005323. Online ahead of print.
PubMed 42400209